Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 1 #1
TickerAZN [NYSE]
CompanyAstraZeneca PLC
CountryUnited Kingdom
IndustryDrug Manufacturers - Major
Market Cap90.13BEPS (ttm)0.98
P/E72.78EPS this Y-52.00%
Forward P/E17.82EPS next Y-4.51%
PEG23.86EPS past 5Y-28.40%
P/S3.45EPS next 5Y3.05%
P/B4.59EPS Q/Q40.50%
Dividend5.33%Sales Q/Q-2.40%
Insider Own-Inst Own7.40%
Insider Trans-Inst Trans-0.54%
Short Float0.10%EarningsApr 24/b
Analyst Recom2.50Target Price75.72
Avg Volume1.58M52W Range60.72 - 79.38
Apr-17-15 05:26PMJohnson & Johnson's New Billion-Dollar Blockbuster at Investopedia
Apr-17-15 08:51AM[video]Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom at TheStreet
Apr-17-15 06:10AM6:10 am AstraZeneca confirms that the FDA has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma
Apr-17-15 03:07AMAstraZeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291 at noodls
Apr-17-15 03:00AMAstraZeneca lung cancer drug delays disease by more than a year Reuters
Apr-17-15 02:03AMSelumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma at noodls
Apr-16-15 06:04PMAstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog